Skip to main content
. 2023 May 19;13(8):3382–3399. doi: 10.1016/j.apsb.2023.05.017

Figure 8.

Figure 8

BAP1 deletion impairs PT33 sensitizing CRC to radiotherapy. (A, B) Representative images and statistical analysis of colony formation assays in BAP1-WT and BAP1-KO cells treated with PT33 (25 nmol/L) and IR at the indicated dose. Data are shown as mean ± SD (n = 3; two-way ANOVA; n. s., not significant; ∗∗P < 0.01 ∗∗∗P < 0.001). (C, D) Representative images (upper) and quantitative analysis (below) of 3D-spheroid formation assays for BAP1-WT and BAP1-KO HCT116 (C) and HCT15 (D) cells treated as in Fig. 7E. For spheroid number, data are mean ± SD (n = 3); for spheroid diameter, data are all spheroids in each well from 3 independent biological replicates and shown as mean ± SD. Statistical significance was determined by two-way ANOVA (n.s, not significant; ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001; blue symbols: compared to corresponding NonIR group; red symbols: compared to PT33 0 nmol/L + IR group). (E, F) BAP1-WT and BAP1-KO HCT116 xenografts were treated alternately with PT33 (1 mg/kg/day for 7 times, normal saline (NS) as control) and IR (1 Gy/day for 7 times). Representative images of tumors (E) and quantitative analysis of tumor volume (F). Data are mean ± SD (n = 5/group). Statistical significance was determined by two-way ANOVA (n.s., not significant; ∗∗P < 0.01).